Education
About Us
Working with TipRanks
Follow Us
ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
RESEARCH TOOLSreports
AVBP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.35 - $36.37
Previous CloseN/A
Volume49.09K
Average Volume (3M)241.60K
Market Cap
$625.39M
Enterprise Value$509.18M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.21
Next Earnings
May 07, 2025EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.40
Shares Outstanding34,016,197
10 Day Avg. Volume334,973
30 Day Avg. Volume241,605
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-10.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.40
Forecast
1Y Price Target
$39.75Price Target Upside113.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
ArriVent BioPharma, Inc. News
---
Bulls Say, Bears Say
Bulls Say
Drug EfficacyFirmonertinib demonstrated a 78.6% and 46.2% ORR in treatment-naïve and pretreated patients, respectively, which compares favorably to those achieved by the majority of competitor agents.
Financial StabilityArriVent ended 3Q24 with $282.9M in cash, cash equivalents, and marketable securities, which should provide an operational runway into 2026 and through multiple clinical data readouts.
Market OpportunityThere is currently no FDA-approved agent for non-small cell lung cancer patients with EGFR PACC mutations, highlighting the potential market opportunity for firmonertinib.
Bears Say
Financial ConcernsThe company has less than two years of cash runway remaining, which may pose financial challenges.
Investor SkepticismThe short interest in the stock is 21.8% of the float, which could indicate some skepticism among investors.
Regulatory UncertaintyIt is unclear whether a registrational, single-arm trial will be enough for approval, or whether a randomized controlled study will be needed for firmonertinib.
---
Ownership Overview
1.53% Insiders
12.39% Mutual Funds
4.39% Other Institutional Investors
72.34% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
AVBP FAQ
What was ArriVent BioPharma, Inc.’s price range in the past 12 months?
ArriVent BioPharma, Inc. lowest stock price was $14.35 and its highest was $36.37 in the past 12 months.
What is ArriVent BioPharma, Inc.’s market cap?
ArriVent BioPharma, Inc.’s market cap is $625.39M.
When is ArriVent BioPharma, Inc.’s upcoming earnings report date?
ArriVent BioPharma, Inc.’s upcoming earnings report date is May 07, 2025 which is in 20 days.
How were ArriVent BioPharma, Inc.’s earnings last quarter?
ArriVent BioPharma, Inc. released its earnings results on Mar 03, 2025. The company reported -$0.6 earnings per share for the quarter, beating the consensus estimate of -$0.665 by $0.065.
Is ArriVent BioPharma, Inc. overvalued?
According to Wall Street analysts ArriVent BioPharma, Inc.’s price is currently Undervalued.
Does ArriVent BioPharma, Inc. pay dividends?
ArriVent BioPharma, Inc. does not currently pay dividends.
What is ArriVent BioPharma, Inc.’s EPS estimate?
ArriVent BioPharma, Inc.’s EPS estimate is -0.66.
How many shares outstanding does ArriVent BioPharma, Inc. have?
ArriVent BioPharma, Inc. has 34,016,197 shares outstanding.
What happened to ArriVent BioPharma, Inc.’s price movement after its last earnings report?
ArriVent BioPharma, Inc. reported an EPS of -$0.6 in its last earnings report, beating expectations of -$0.665. Following the earnings report the stock price went down -6.692%.
Which hedge fund is a major shareholder of ArriVent BioPharma, Inc.?
Currently, no hedge funds are holding shares in AVBP
---
ArriVent BioPharma, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.75 (113.37% Upside)
$39.75 (113.37% Upside)
Hedge Fund Trend
Decreased
By 390.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.58%
12-Months-Change
Fundamentals
Return on Equity
-39.36%
Trailing 12-Months
Asset Growth
68.57%
Trailing 12-Months
Company Description
ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
---
AVBP Stock 12 Month Forecast
Average Price Target
$39.75
▲(113.37% Upside)
Technical Analysis
Arbutus Biopharma
―
Xencor
―
Rocket Pharmaceuticals
―
Nuvation Bio
―
Praxis Precision Medicines
―
Best Analysts Covering AVBP
1 Year
1 Year Success Rate
2/8 ratings generated profit
1 Year Average Return
-16.40%
reiterated a buy rating last month
Copying Robert Burns's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -16.40% per trade.
---